Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04221503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Niraparib/TTFields in GBM

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: University of Pennsylvania to Abramson Cancer Center at Penn Medicinev10
  2. Primary and study completion dates: Dec 2025 to Jan 2026v9
  3. Re-verified, no change to tracked fieldsv8
  4. Trial status: Recruiting to Active, Not Recruiting Site details revisedv7 Show 1 more changeShow less
    • Site details revised
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria expanded, about 42 wordsv5 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Active, Not Recruiting to Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  3. Trial status: Recruiting to Active, Not Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  4. Start date changed from estimate of Jan 2020 to Dec 30, 2019 Study description expanded, about 6 wordsv2 Show 1 more changeShow less
    • Study description expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
Trial Details
NCT Number NCT04221503
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Tesaro, Inc., NovoCure Ltd.
Conditions Glioblastoma, Recurrent Glioblastoma, GBM
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov